Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › enzalutamide

enzalutamide

5 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of enzalutamide

72 trials tracked of enzalutamide: 17 in phase 3 or 4 and 11 with published results. The most-cited published study has 1176 citations.

72Trials tracked
17Phase 3 & 4
0Recruiting
11With published results
Phase distribution
Phase 4 6 Phase 3 11 Phase 2 47 Phase 1 5 Other / NA 3
  1. Phase 3 A Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) Completed · 1,176 cited
  2. Phase 3 A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen Completed · 241 cited
  3. Phase 4 Safety Study of Continued Enzalutamide Treatment In Prostate Cancer Patients Completed · 171 cited
  4. Phase 3 Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-7339-010/KEYLYNK-010) Completed · 131 cited
  5. Phase 4 A Study to Evaluate Enzalutamide After Abiraterone in Metastatic Castration-Resistant Prostate Cancer Completed · 117 cited
  6. Phase 3 Study of Olaparib (Lynparza™) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer (PROfound Study) Completed · 91 cited
Show 44 more trials
  1. Phase 4 Cabazitaxel Versus the Switch to Alternative AR-targeted Agent (Enzalutamide or Abiraterone) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients Previously Treated With Docetaxel and Who Rapidly Failed a Prior AR-targeted Agent Completed · 65 cited
  2. Phase 3 A Study to Assess the Benefit of Treatment Beyond Progression With Enzalutamide in Men Who Are Starting Treatment With Docetaxel After Worsening of Their Prostate Cancer When Taking Enzalutamide Alone Completed · 39 cited
  3. Phase 3 Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991) Completed · 24 cited
  4. Phase 3 An Asian Study to Evaluate Efficacy and Safety of Oral Enzalutamide in Progressive Metastatic Prostate Cancer Participants Completed · 20 cited
  5. Phase 3 Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer Completed · 20 cited
  6. Phase 4 A Study to Evaluate the Potential Increased Risk of Seizures Among Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Treated With Enzalutamide Completed
  7. Phase 4 Study on Enzalutamide and Flutamide in Patients With Castration Resistant Prostate Cancer Completed
  8. Phase 4 A Safety and Efficacy Study of Enzalutamide in Indian Patients With Progressive Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated With Docetaxel-Based Chemotherapy Completed
  9. Phase 3 Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)-China Extension Completed
  10. Phase 3 A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer Completed
  11. Phase 3 Safety and Efficacy Study of MDV3100 in Patients With Castration-Resistant Prostate Cancer Who Have Been Previously Treated With Docetaxel-based Chemotherapy Completed
  12. Phase 2 A Study of Enzalutamide Versus Bicalutamide in Castrate Men With Metastatic Prostate Cancer Completed
  13. Phase 2 Biomarker-Driven Therapy With Nivolumab and Ipilimumab in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Expressing AR-V7 Completed
  14. Phase 2 A Positron Emission Tomography/Computed Tomography (PET/CT) Bone Imaging Study in Patients Receiving Enzalutamide for Castration-Resistant Prostate Cancer (CRPC) Completed
  15. Phase 2 Enzalutamide, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrioid Endometrial Cancer Completed
  16. Phase 2 Enzalutamide and Paclitaxel Before Surgery in Treating Patients With Stage I-III Androgen Receptor-Positive Triple-Negative Breast Cancer Completed
  17. Phase 2 Randomized Salvage Radiation Therapy Plus Enzalutamide Post Prostatectomy Completed
  18. Phase 2 A Study of Enzalutamide and LY3023414 in Men With Prostate Cancer Completed
  19. Phase 2 Pertuzumab, Trastuzumab, Hyaluronidase-zzxf and Enzalutamide for Treatment of Metastatic Castration-Resistant Prostate Cancer Completed
  20. Phase 2 Radium Ra 223 With Enzalutamide Compared to Enzalutamide Alone in Men With Metastatic Castration Refractory Prostate Cancer Completed
  21. Phase 2 RE-sensitizing With Supraphysiologic Testosterone to Overcome REsistance (The RESTORE Study) Completed
  22. Phase 2 Addition of Opaganib to Androgen Antagonists in Patients With mCRPC Completed
  23. Phase 2 A Study Called ARAMON to Learn to What Extent Does Study Treatment With Darolutamide Affects Testosterone Levels in Men With Prostate Cancer That Had Not Been Treated With Hormonal Therapy Compared to Treatment With Enzalutamide Completed
  24. Phase 2 I-131-1095 Radioligand Plus Enzalutamide vs Enzalutamide for mCRPC That Progressed During Abiraterone (ARROW). Completed
  25. Phase 2 A Study of ZEN003694 in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer Completed
  26. Phase 2 Enzalutamide and Mifepristone in Treating Patients With Metastatic Hormone Resistant Prostate Cancer Completed
  27. Phase 2 ProSTAR: A Study Evaluating CPI-1205 in Patients With Metastatic Castration Resistant Prostate Cancer Completed
  28. Phase 2 Abiraterone Acetate Plus LHRH Agonist and Abiraterone Acetate Plus LHRH Agonist and Enzalutamide Completed
  29. Phase 2 Study of Enzalutamide in Patients With Castration-resistant Prostate Cancer Completed
  30. Phase 2 A Study to Assess the Efficacy and Safety of Enzalutamide in Subjects With Advanced Hepatocellular Carcinoma Completed
  31. Phase 2 Safety and Efficacy Study of Enzalutamide in Patients With Advanced, Androgen Receptor-Positive, Triple Negative Breast Cancer Completed
  32. Phase 2 A Study to Test if Enzalutamide is Effective and Safe in Prostate Cancer Patients Who Have Never Had Hormone Therapy Completed
  33. Phase 2 LHRH Analogue Therapy With Enzalutamide or Bicalutamide in Treating Patients With Hormone Sensitive Prostate Cancer Completed
  34. Phase 2 Salvage Therapeutic Radiation With Enzalutamide and ADT in Men With Recurrent Prostate Cancer (STREAM) Completed
  35. Phase 2 Enzalutamide/Leuprolide +/- Abiraterone/Pred in Prostate Completed
  36. Phase 2 Enzalutamide With or Without Vaccine Therapy for Advanced Prostate Cancer Completed
  37. Phase 2 Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer Completed
  38. Phase 2 Enzalutamide and Hormone Therapy Before, During, and After Radiation for High Risk Localized Prostate Cancer Completed
  39. Phase 2 Enzalutamide Versus Standard Androgen Deprivation Therapy for the Treatment Hormone Sensitive Prostate Cancer Completed
  40. Phase 2 Enzalutamide in Patients With High-risk Prostate Cancer Completed
  41. Phase 2 Study of TRC105 With Abiraterone and With Enzalutamide in Prostate Cancer Patients Progressing on Therapy Completed
  42. Phase 2 Genetic and Molecular Mechanisms in Assessing Response in Patients With Prostate Cancer Receiving Enzalutamide Therapy Completed
  43. Phase 2 EXTEND Exercise Trial Completed
  44. Phase 2 Study of Enzalutamide (Formerly MDV3100) as a Neoadjuvant Therapy for Patients Undergoing Prostatectomy for Localized Prostate Cancer Completed

Showing the 50 most-cited and recently-updated of 72 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Enzalutamide plus ADT improves 5-year survival in metastatic hormone-sensitive prostate cancer
Urology RCT
Enzalutamide plus ADT improves 5-year survival in metastatic hormone-sensitive prostate cancer Prostate Cancer Drug Helps Men Live Years Longer, New Data Shows
This post hoc analysis of a phase 3 randomized controlled trial in 1150 patients with metastatic hormone-sensitive prostate cancer found tha…
Men with advanced prostate cancer who took enzalutamide lived years longer than those on standard treatment alone, according to five-year da…
May 7, 2026
Enzalutamide plus radium-223 extends survival in metastatic castration-resistant prostate cancer
Urology RCT
Enzalutamide plus radium-223 extends survival in metastatic castration-resistant prostate cancer Adding Radium-223 to enzalutamide extends life for advanced prostate cancer patients
This phase 3 randomized controlled trial in 446 patients with metastatic castration-resistant prostate cancer compared enzalutamide plus rad…
Adding a specific bone-targeting drug to standard treatment helps men with advanced prostate cancer live longer while managing side effects …
May 3, 2026
PSA levels at 6, 12, and 24 weeks post-randomization correlate with 96-month survival in prostate cancer
Oncology RCT
PSA levels at 6, 12, and 24 weeks post-randomization correlate with 96-month survival in prostate cancer Low PSA at 24 weeks predicts longer survival in prostate cancer
This post-hoc analysis of five phase 3 trials in 7129 patients with prostate cancer found that 96-month overall survival varied by metastati…
Men with prostate cancer who hit a PSA level of 0.2 ng/mL or less within 24 weeks of starting treatment are far more likely to survive at le…
May 1, 2026
Enzalutamide Monotherapy Shows Higher Survival and Metastasis-Free Rates Versus Leuprolide in High-Risk Biochemical Recurrence
Drug Pipeline RCT
Enzalutamide Monotherapy Shows Higher Survival and Metastasis-Free Rates Versus Leuprolide in High-Risk Biochemical Recurrence Enzalutamide shows better outcomes than leuprolide for high risk prostate cancer recurrence
This Phase 3 randomized controlled trial evaluated enzalutamide monotherapy versus leuprolide alone in patients with high-risk biochemical r…
Men with high-risk prostate cancer recurrence lived longer and spread less cancer when taking enzalutamide alone instead of leuprolide alone…
Apr 19, 2026
Deutenzalutamide improves rPFS in mCRPC after abiraterone and docetaxel progression
Oncology RCT
Deutenzalutamide improves rPFS in mCRPC after abiraterone and docetaxel progression New Pill Slows Advanced Prostate Cancer After Other Drugs Fail
A randomized phase III trial in 417 patients with metastatic castration-resistant prostate cancer after progression on or intolerance to abi…
A new daily pill slowed advanced prostate cancer progression by 42 percent in men whose disease grew despite standard hormone therapy and ch…
Apr 15, 2026